Sugi Predict

Sugi Predict / Compounds / SCHEMBL6989909

SCHEMBL6989909

SCHEMBL6989909

CC(C)(C)C(NC(=O)c1cccc(Cl)c1)Nc1c(Nc2cccnc2C(F)(F)F)c(=O)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPT P10636 3/20 0.39
▸ HTT P42858 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ ALOX12 P18054 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ S1PR4 O95977 4/20 0.38
▸ S1PR3 Q99500 4/20 0.38
▸ S1PR2 O95136 2/20 0.38
▸ DPP4 P27487 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KCNJ11 Q14654 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6983246 0.90 KMT2A (0.44) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL6991631 0.89 MAPT (0.38) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL6987149 0.86 MEN1 (0.41) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL6989259 0.84 ALDH1A1 (0.46) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL6986478 0.83 KMT2A (0.43) KMT2AMAPTHTTALDH1A1LMNA
SCHEMBL7559791 0.82 POLB (0.42) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL4256402 0.82 POLB (0.42) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL4256399 0.82 POLB (0.42) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL6985145 0.81 KMT2A (0.56) KMT2AMEN1L3MBTL1MAPTHTT
SCHEMBL6985814 0.81 KCNJ11 (0.52) KMT2AMEN1MAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 — — EP disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 — — US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 — — US disclosed
US-20020147230-A1 Aminal Diones as potassium channel openers ABBOTT LABORATORIES 2002-10-10 — — US disclosed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147230-A1 Aminal Diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 KMT2A 1875/4885MEN1 773/4885L3MBTL1 1654/4885
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 KMT2A 1875/4885MEN1 773/4885L3MBTL1 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.